Plasma fractionation issues

Albert Farrugia, Theo Evers, Pierre Francois Falcou, Thierry Burnouf, Luiz Amorim, Sylvia Thomas

研究成果: 雜誌貢獻文章同行評審

34 引文 斯高帕斯(Scopus)

摘要

Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.
原文英語
頁(從 - 到)88-93
頁數6
期刊Biologicals
37
發行號2
DOIs
出版狀態已發佈 - 4月 2009
對外發佈

ASJC Scopus subject areas

  • 生物技術
  • 應用微生物與生物技術
  • 生物工程
  • 免疫學與微生物學 (全部)
  • 藥理

指紋

深入研究「Plasma fractionation issues」主題。共同形成了獨特的指紋。

引用此